The eXalt3 trial included 290 ALK-positive, TKI-naïve patients with stage IIIB/IV NSCLC treated with up to one line of prior chemotherapy. Ensartinib demonstrated a significantly improved blinded independent review committee-assessed PFS of 25.8 months compared to crizotinib of 12.7 months, HR 0.51 (95% CI 0.35-0.72, p=0.0001). READ ARTICLE
Oncology Times DOI:10.1097/01.COT.0000721308.30680.3f
Authors: Selina Wong, Amanda Cass and Leora Horn
